Document is current
Any future updates will be listed below
-
Authors
Lupidi, Marco https://orcid.org/0000-0002-6817-2488
Bandello, Francesco
Vujosevic, Stela
Parravano, Mariacristina
Bacherini, Daniela
Minnella, Angelo Maria
Giansanti, Fabrizio
Ascardi, Chiara
Staurenghi, Giovanni
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04774926 at ClinicalTrials.govDocuments that mention this clinical trial
Multimodal Imaging to Assess Disease Activity and Predict Fluid Resolution in Patients with wAMD Treated with Brolucizumab: The IMAGINE Study
https://doi.org/10.1007/s40123-025-01229-5
-
Funding
Funding for this research was provided by:
Italian Ministry of Health, ricerca corrente, and Fondazione Roma
Novartis Farma SpA
- License Information
-
More Information
Article History
Received: 13 June 2025
Accepted: 6 August 2025
First Online: 20 August 2025
Declarations
:
: Marco Lupidi serves as Advisory Board member for Abbvie, Apellis, Bayer, Novartis, and Roche. Mariacristina Parravano reports personal fees from Abbvie, Novartis, Bayer, and Roche outside of the submitted work. Francesco Bandello, Stela Vujosevic, Daniela Bacherini, Angelo Maria Minnella, Fabrizio Giansanti, Chiara Ascardi, and Giovanni Staurenghi have no conflicts of interest to declare.
: The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines. The study protocol (EudraCT no. 2020–002452-20) was reviewed and approved by the IRCCS Ospedale San Raffaele Ethics Committee in December 2020 (approval no. 332/2020). The trial was registered with ClinicalTrials.gov (ClinicalTrials.gov ID NCT04774926).
